Evidence map›Paper›PMID 41581069›Full record

ArticleACS chemical neuroscience2026

Discovery of VU6025733 (AG06827): A Highly Selective, Orally Bioavailable, and Structurally Distinct M

Alison R Gregro, Charlotte Park, Madeline F Long, Logan A Baker, Katrina A Bollinger, Anna E Ringuette, Li Peng, Vincent B Luscombe, Natasha B Billard, Alice L Rodriguez and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Alison R GregroWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Charlotte ParkWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Madeline F LongWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0002-8933-3439
Logan A BakerWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Katrina A BollingerWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Anna E RinguetteWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Li PengWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Vincent B LuscombeWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Natasha B BillardWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Alice L RodriguezWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0002-5244-5103
Colleen M NiswenderWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0001-6009-8212
Weimin PengDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Jonathan W DickersonDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Jerri M RookDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.
Jordan O'NeillWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Sichen ChangWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Harrie C M BoonenNeuroscience Drug Discovery Denmark, H. Lundbeck A/S, 9 Ottiliavej, Valby, Copenhagen DK-2500, Denmark.ORCID 0000-0003-2713-7106
Thomas JensenNeuroscience Drug Discovery Denmark, H. Lundbeck A/S, 9 Ottiliavej, Valby, Copenhagen DK-2500, Denmark.
Morten S ThomsenNeuroscience Drug Discovery Denmark, H. Lundbeck A/S, 9 Ottiliavej, Valby, Copenhagen DK-2500, Denmark.ORCID 0000-0002-5072-0351
Thomas M BridgesWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Olivier BoutaudWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
P Jeffrey ConnWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Darren W EngersWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Craig W LindsleyWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0003-0168-1445
Kayla J TempleWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0001-5290-574X

Funding

The Vanderbilt Specialized Chemistry Center for Accelerated Probe DevelopmentU54MH084659 · NIMH · VANDERBILT UNIVERSITY · PI LINDSLEY, CRAIG · 2008 to 2013
$24.1M
Vanderbilt NCDDDG for Discovery of Novel Treatments for SchizophreniaU01MH087965 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY, LINDSLEY, CRAIG · 2010 to 2014
$9.3M
NIMH NIH HHS U01 MH087965NIMH NIH HHS U54 MH084659
6 · The paper itself

Abstract

This work describes progress toward an M

Indexed as

PiperidinesPyridazinesReceptor, Muscarinic M4TriazolesAdministration, OralAllosteric RegulationAnimalsBiological AvailabilityDose-Response Relationship, DrugHumansMaleRatsRats, Sprague-DawleyStructure-Activity RelationshipPiperidinesPyridazinesReceptor, Muscarinic M4TriazolesAlzheimer’s diseaseM4muscarinic acetylcholine receptor (mAChR)parkinson’s diseasePositive allosteric modulator (PAM)schizophreniastructure−activity relationship (SAR)

Identifiers

PMID41581069
PMCPMC12879736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.